Literature DB >> 6255864

Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

T O Kurtz, D J Winston, J A Hindler, L S Young, W L Hewitt, W J Martin.   

Abstract

The in vitro activities of four new beta-lactam antimicrobial agents (moxalactam, cefotaxime, cefoperazone, and piperacillin) and the aminoglycosides against 744 recent clinical isolates of facultative gram-negative bacilli were compared simultaneously by the agar dilution method. The major in vitro difference of these newer beta-lactam compounds appeared to be their antipseudomonal activity; cefoperazone was the most active, whereas cefotaxime had the least potency. The aminoglycosides, however, had the most effective in vitro activity on a weight basis against Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255864      PMCID: PMC284064          DOI: 10.1128/AAC.18.4.645

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

2.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

3.  In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin.

Authors:  N Matsubara; S Minami; T Muraoka; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.

Authors:  J P Sosna; P R Murray; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

5.  In vitro studies with netilmicin compared with amikacin, gentamicin, and tobramycin.

Authors:  V Dhawan; E Marso; W J Martin; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

6.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

7.  Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

Authors:  V L Yu; R M Vickers; J J Zuravleff
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

8.  Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

Authors:  M V Borobio; J Aznar; R Jimenez; F Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  23 in total

1.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

2.  Susceptibility of clinical isolates to cefoperazone.

Authors:  D A Bremner
Journal:  Drugs       Date:  1981       Impact factor: 9.546

3.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  In vitro activity of cefotaxime against clinically significant pathogens.

Authors:  S Nakashio; M Nakamura
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.

Authors:  P H Karakusis; G M Trenholme; S Levin
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.

Authors:  G M Eliopoulos; A Gardella; P DeGirolami; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

8.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.

Authors:  C R Magnussen; M T Sammartino; K D Ernest
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.